Cardiovascular Disease Atlas
Data release 1.0
| Disease | Cardiomyopathy |
|---|---|
| CVD Atlas ID | CVDD000014 |
| MeSH ID | D009202 |
| Ontology ID | NCIT:C34830 |
| Description [MeSH] | A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). |
| Dataset | Reported disease | Tissue/cell type | Omics | Data accession |
|---|---|---|---|---|
| CVDS000295 | Atherosclerosis of the extremities (PheCode 440.2) | - | Genomics | GCST90044005 |
| CVDS000296 | Atherosclerosis (PheCode 440) | - | Genomics | GCST90044006 |
| CVDS000506 | Atherosclerosis | Artery | Epigenomics | GSE149759 |
| CVDS000529 | Atherosclerosis | Peripheral blood mononuclear cell | Transcriptomics | GSE230214 |
| CVDS000531 | Atherosclerosis | Macrophage | Transcriptomics | GSE9874 |
| Variant | Gene | Beta | Standard error | P value | Odds ratio | Study | Ancestry | Link |
|---|
| Gene | Tissue | Best coloc SNP | GWAS risk SNP | SNP.PP.H4 | PP.H4.abf | Ancestry | Dataset |
|---|
| Variant | Gene | Description | PMID |
|---|---|---|---|
| No data available in table | |||
| Variant | Pre miRNA | Region | Mature miRNA |
ΔG
|
Predict
| PMID |
|---|---|---|---|---|---|---|
| No data available in table | ||||||
| SNP | Reported disease | Gene | Description | PMID |
|---|---|---|---|---|
| No data available in table | ||||
| Reported disease | Gene | Category | Description | Publication |
|---|---|---|---|---|
| No data available in table | ||||
| Tissue/cell type | Gene | Reported disease | Alteration | log2FC | P value | Adjusted P value | Method | PMID |
|---|---|---|---|---|---|---|---|---|
| Aorta | COL15A1 | Atherosclerosis | Up | 0.00 | - | - | qRT-PCR | 23912340 |
| Carotid artery segment | SNHG12 | Atherosclerosis | Down | 0.00 | - | - | qPCR | 32075942 |
| Peripheral blood mononuclear cell | CCR7 | Atherosclerosis | Down | 0.00 | - | - | qPCR | 32178422 |
| Peripheral blood mononuclear cell | FOXO1 | Atherosclerosis | Down | 0.00 | - | - | qPCR | 32178422 |
| Tissue/cell type | Gene | Reported disease | Mapped disease | log2FC | P value | Adjusted P value | Method | Dataset |
|---|---|---|---|---|---|---|---|---|
| Macrophage | MT2A | Atherosclerosis | Atherosclerosis | 1.25e+3 | 4.04e-5 | 1.17e-3 | Microarray | CVDS000531 |
| Macrophage | TALDO1 | Atherosclerosis | Atherosclerosis | 1.23e+3 | 1.52e-13 | 4.67e-11 | Microarray | CVDS000531 |
| Macrophage | PLIN2 | Atherosclerosis | Atherosclerosis | 1.09e+3 | 1.07e-17 | 8.88e-15 | Microarray | CVDS000531 |
| Macrophage | PRDX1 | Atherosclerosis | Atherosclerosis | 1.09e+3 | 1.46e-9 | 1.56e-7 | Microarray | CVDS000531 |
| Macrophage | APOC1 | Atherosclerosis | Atherosclerosis | 1.05e+3 | 6.51e-6 | 2.57e-4 | Microarray | CVDS000531 |
| Macrophage | MT1H | Atherosclerosis | Atherosclerosis | 926 | 3.91e-5 | 1.15e-3 | Microarray | CVDS000531 |
| Macrophage | TXNRD1 | Atherosclerosis | Atherosclerosis | 730 | 4.04e-13 | 1.09e-10 | Microarray | CVDS000531 |
| Macrophage | AKR1B1 | Atherosclerosis | Atherosclerosis | 636 | 1.75e-7 | 1.17e-5 | Microarray | CVDS000531 |
| Macrophage | ANXA1 | Atherosclerosis | Atherosclerosis | 630 | 1.18e-5 | 4.33e-4 | Microarray | CVDS000531 |
| Macrophage | UBB | Atherosclerosis | Atherosclerosis | 620 | 1.76e-3 | 2.50e-2 | Microarray | CVDS000531 |
| Gene | Gene type | Species | Reported disease | Score | PMID | Gene link |
|---|
| Reported disease | Tissue | Gene | Effect size | P value | Method | Publication | PMID | Gene link |
|---|---|---|---|---|---|---|---|---|
| No data available in table | ||||||||
| Reported disease | Gene | Category | Description | Publication |
|---|---|---|---|---|
| Atherosclerosis | hsa-mir-106a | genetics_overexpression_promote | CONCLUSION: Overexpression of GASL1 might suppress ox-LDL-induced HUVEC cell viability, apoptosis, and inflammation by regulating miR-106a/LKB1 axis. | 36627571 |
| Atherosclerosis | hsa-mir-197 | circulation_biomarker_diagnosis_ns | 3p was decreased in the serum of AS patients compared to healthy donors. | 36523143 |
| Atherosclerosis | MIR33A | circulation_biomarker_diagnosis_up | 5p in serum and the liver. | 36286043 |
| Atherosclerosis | MIR122 | circulation_biomarker_diagnosis_up | 5p in serum and the liver. | 36286043 |
| Atherosclerosis | MIR21 | circulation_biomarker_diagnosis_up | 5p in serum and the liver. | 36286043 |
| Atherosclerosis | MIR576 | circulation_biomarker_diagnosis_ns | 3p/IFIT1/STAT1 feedback loop participates in atherosclerosis progression and contributes to the high circ_0086296 expression observed in the exosomes of serum of patients with atherosclerosis. | 36138395 |
| Atherosclerosis | hsa-mir-155 | circulation_biomarker_diagnosis_ns | Moreover, detection of circulating EVs-carried miR-155 expression may reveal the progression of atherosclerosis. On the molecular level, blocking miR-155 biogenesis, which constituted a novel therapeutic approach, may protect against nicotine aggravating atherosclerosis. | 36006370 |
| Atherosclerosis | hsa-mir-130a | circulation_biomarker_prognosis_ns | CONCLUSION: All the findings indicated that high serum miR-130a-3p had diagnostic potential to screen cerebral AS, and predicted the probability of cerebrovascular events after AS. | 35996079 |
| Atherosclerosis | hsa-mir-99a | genetics_overexpression_promote | In vivo, the specific overexpression of miR-99a-5p significantly reduced atherosclerotic lesions, accompanied by a significant downregulation of autophagy marker CD68 protein expression. | 35968506 |
| Atherosclerosis | hsa-mir-224 | genetics_knock down_suppress | Knockdown of HCG11 alleviated cell pyroptosis and inflammation induced by ox-LDL via targeting the miR3p/JAK1 axis, indicating that HCG11 could be the latent target of diagnosis or treatment for AS. | 35931919 |
| Reported disease | Gene | Species | Description | Publication |
|---|---|---|---|---|
| Atherosclerosis | CCR7 | Homo sapiens | This allowed the identification ofFOXO1andCCR7as blood markers downregulated in CAD. | 32178422 |
| Atherosclerosis | CD52 | Homo sapiens | This study has established that CD52 and IL1RN may play a key role in the occurrence and development of atherosclerosis, which opens new lines of thought for further research on the pathogenesis of atherosclerosis. | 37173673 |
| Atherosclerosis | CDKN2B-AS1 | Homo sapiens | The results demonstrated that CDKN2B-AS1 promotes atherosclerotic plaque formation and inhibits mRCT in atherosclerosis by regulating CDKN2B promoter, and thereby could be a potential therapeutic target for atherosclerosis. | 32335370 |
| Atherosclerosis | CHAER1 | Homo sapiens | We found that the Chaer was highly expressed in serum samples from 28 patients with atherosclerosis, compared with 28 healthy volunteers. Chaer was dramatically Upregulated in atherosclerotic plaques of ApoE-/- mice. We also found that the expression of Chaer was Upregulated in vascular smooth muscle cell injury model. Through loss- and gain-of-function approaches, we showed that Chaer promotes cell proliferation and induces apoptosis in vitro. Mechanistically, Chaer interacts with Polycomb Repressor Complex 2 (PRC2) through inhibiting histone H3 lysine 27 methylation. Further, this interaction is induced Upon mTOR signaling pathway. | 31539156 |
| Atherosclerosis | COLCA1 | Homo sapiens | OxLDL can Up-regulate the expression ofCOLCA1in HCAECs, which in turn affects the intracellularCOLCA1/hsa-miR-371a-5p/SPP1pathway to regulate the level of oxidative stress in cells. | 35434044 |
| Atherosclerosis | DNMT3B | Homo sapiens | DNMT3b accelerated atherosclerosis, and may be associated with FOXP3 hypermethylation status in regulatory T cells. | 35422896 |
| Atherosclerosis | FGF7-5 | Homo sapiens | these findings indicated that lncRNA_FGF7-5 and lncRNA_GLRX3 together reduced atherosclerosis-induced apoptosis of HUVECs via targeting miR-2681-5p to increase ERCC4 expression, thereby preventing the formation of carotid plaque and finally inhibiting atherosclerosis progression. | 36071684 |
| Atherosclerosis | FHL5 | Homo sapiens | FHL5, IBSP, and SCRG1 have been identified as the diagnostic genes in AS. | 35663954 |
| Atherosclerosis | FOS | Homo sapiens | The Finkel-Biskis-Jinkins osteosarcoma (FOS) gene was significantly increased in patients, and the highest levels of FOS associated with patients who had previously undergone coronary revascularization | 15728378 |
| Atherosclerosis | FOXO1 | Homo sapiens | This allowed the identification ofFOXO1andCCR7as blood markers downregulated in CAD. | 32178422 |
| Name | Gene | Relation to gene | Tissue | Reported disease | Delta beta | P value | Adjusted P value | Dataset | GEO accession |
|---|
| Name | Gene | Relation to gene | Reported disease | Delta beta | P value | Adjusted P value | Tissue | PMID |
|---|
| Reported disease | Gene | Category | Description | Publication |
|---|---|---|---|---|
| No data available in table | ||||
| Reported disease | Gene | Species | Description | Publication |
|---|---|---|---|---|
| No data available in table | ||||
| Gene | Protein | Average log2FC | P value | Dataset |
|---|---|---|---|---|
| No data available in table | ||||
| Metabolite | VIP | Dataset |
|---|---|---|
| No data available in table | ||
| Chemical name | Chemical ID | Direct evidence | Reported disease | Inference gene | Inference score | #PMIDs | Gene link |
|---|